Freestone Capital Holdings’s Takeda Pharmaceutical TAK Stock Holding History

Freestone Capital Holdings’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-48,624	Closed	-$696K	–	571
2022 Q1	$696K	Buy	48,624 +35,928	+283%	+$528K	0.03%	294
2021 Q4	$173K	Buy	+12,696	New	+$178K	0.01%	481
2021 Q3	–	Sell	-11,016	Closed	-$185K	–	439
2021 Q2	$185K	Sell	11,016 -3,467	-24%	-$59K	0.01%	398
2021 Q1	$264K	Sell	14,483 -59,805	-81%	-$1.08M	0.01%	345
2020 Q4	$1.35M	Sell	74,288 -76,407	-51%	-$1.34M	0.08%	180
2020 Q3	$2.69M	Sell	150,695 -28,019	-16%	-$510K	0.18%	122
2020 Q2	$3.2M	Sell	178,714 -16,101	-8%	-$289K	0.04%	117
2020 Q1	$2.96M	Buy	194,815 +72,227	+59%	+$1.31M	0.06%	108
2019 Q4	$2.42M	Buy	122,588 +3,594	+3%	+$68.8K	0.05%	160
2019 Q3	$2.05M	Buy	118,994 +22,539	+23%	+$390K	0.05%	172
2019 Q2	$1.71M	Buy	96,455 +16,642	+21%	+$303K	0.04%	176
2019 Q1	$1.63M	Buy	79,813 +49,691	+165%	+$1,000K	0.1%	173
2018 Q4	$507K	Buy	+30,122	New	+$509K	0.03%	287

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Freestone Capital Holdings's TAK Position: Q2 2022 in Review

Freestone Capital Holdings sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 48,624 shares — an estimated $696K sold.

Freestone Capital Holdings first reported a position in TAK in Q4 2018 and held it in 13 quarters. The position peaked at $3.2M in Q2 2020. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

Freestone Capital Holdings reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Freestone Capital Holdings sold 48,624 Takeda Pharmaceutical shares in Q2 2022, an estimated $696K.
Freestone Capital Holdings first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 13 quarters.
Freestone Capital Holdings's Takeda Pharmaceutical position peaked at $3.2M in Q2 2020.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Freestone Capital Holdings's 13F filing for Q2 2022, filed 9 Aug 2022.